N@N

Cubist Pharmaceuticalsa? Antibiotic Programs Featured in 47 Presentations at 50th ICAAC

^{Published on 2010-09-10 06:40:33 - Market Wire}
 

LEXINGTON, Mass.--([ BUSINESS WIRE ])--[ Cubist Pharmaceuticals, Inc. ] (NASDAQ: CBST) today announced that 47 presentations at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston from September 12-15 will cover recent research related to its marketed antibiotic, CUBICIN® (daptomycin for injection), as well as the companya™s clinical and preclinical antibiotic programs. Included are 43 poster presentations and 4 slide presentations.

• 17 focus on daptomycin or related disease state research.
• 7 focus on preclinical and early stage clinical research relating to Cubista™s CXA-201 program. Cubist is developing CXA-201 as a first-line intravenous therapy for the treatment of serious Gram-negative bacterial infections, including those caused by multi-drug resistant Pseudomonas aeruginosa. CXA-201 is the combination of a novel cephalosporin (CXA-101) with the beta-lactamase inhibitor tazobactam.
• 8 focus on preclinical and early stage clinical research related to Cubista™s Phase 2 oral antibiotic candidate CB-183,315, an antibacterial drug candidate intended to treat patients with a severe and sometimes life-threatening diarrhea caused by Clostridium difficile known as C. difficile-associated diarrhea, or CDAD.
• 15 focus on preclinical research related to Cubist's early stage programs.

Highlights, including brief descriptions and the time of each presentation, are posted at [ cubist.com. ]

Cubist Executive Vice President, Research and Development and Chief Scientific Officer Dr. Steve Gilman said, "Our strong scientific presence at ICAAC demonstrates the vitality of our pipeline and our commitment to addressing unmet medical needs of acutely ill patients. The breadth and depth of scientific inquiry represented in all of the presentations underscores our scientistsa™ dedication to find new medicines to replenish the clinician armamentarium in the fight against some of the dangerous multidrug resistant asuper bugsa™ plaguing society today.a

Cubist has a booth (#315) at ICAAC where our scientists will be available to talk about our advancing clinical pipeline of antibiotic therapies for certain serious infections caused by Gram-positive and multi-drug-resistant Gram-negative pathogens.

About CUBICIN

CUBICIN® (daptomycin for injection) is approved in the U.S. and many other non-US markets as therapy for Staphylococcus aureus bloodstream infections (bacteremia), including right-sided endocarditis, caused by methicillin-resistant S. aureus (MRSA) and methicillin-susceptable S. aureus (MSSA), and complicated skin infections caused by certain Gram-positive bacteria, including MRSA. CUBICIN is not indicated for the treatment of pneumonia. Most adverse events reported in clinical trials were mild to moderate in intensity. The most common were anemia, constipation, diarrhea, nausea, vomiting, injection site reactions, and headache. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CUBICIN, CUBICIN should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria susceptible to CUBICIN. For full prescribing information, including important safety information, please visit [ www.cubicin.com ].

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides. The Cubist clinical product pipeline currently consists of a Phase 2 program, added with Cubista™s acquisition of Calixa Therapeutics Inc. in December 2009, focused on the development of a novel cephalosporin to address certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms; a Phase 2 program for the treatment of CDAD (Clostridium difficile-associated diarrhea); and a Phase 1 program intended to address the unmet medical need for a treatment for serious infections caused by MDR Gram-negative pathogens. Cubist is also working on several pre-clinical programs being developed to address areas of significant medical needs. These include an anti-infective program for the treatment of respiratory syncytial virus (RSV) in children, therapies to treat various serious bacterial infections, and agents to treat acute pain. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubista™s web site at [ www.cubist.com ].

Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.